-
Methods in Molecular Biology (Clifton,... 2023Dendritic cells are cells of hematopoietic origin that are specialized in antigen presentation and instruction of innate and adaptive immune responses. They are a...
Dendritic cells are cells of hematopoietic origin that are specialized in antigen presentation and instruction of innate and adaptive immune responses. They are a heterogenous group of cells populating lymphoid organs and most tissues. Dendritic cells are commonly separated in three main subsets that differ in their developmental paths, phenotype, and functions. Most studies on dendritic cells were done primarily in mice; therefore, in this chapter, we propose to summarize the current knowledge and recent progress on mouse dendritic cell subsets' development, phenotype, and functions.
Topics: Animals; Mice; Dendritic Cells; Phenotype; Antigen Presentation
PubMed: 36905505
DOI: 10.1007/978-1-0716-2938-3_1 -
Cancer Biotherapy & Radiopharmaceuticals Sep 2023Dendritic cells (DCs) are the most important antigen-presenting cells in the body and play a key role in antigen recognition, uptake, processing, and presentation and... (Review)
Review
Dendritic cells (DCs) are the most important antigen-presenting cells in the body and play a key role in antigen recognition, uptake, processing, and presentation and mediate nonspecific immunity and specific immunity. To summarize the main findings that DC vaccines are a new immunotherapy scheme combining the strengths of tumor antigens and DCs that can boost the body's identification and clearance of tumors. In this review, the authors focus on the biological characteristics of DCs, recent advances in the understanding of antitumor mechanisms, and the classification of DC vaccines. The current progress of DC-based vaccine immunotherapy for common tumors with high morbidity or mortality in China were systematically summarize. The DC vaccines combining the strengths of tumor antigens will provide directions to explore reasonable, safe, and effective combination immunotherapy strategies for tumors in the future.
Topics: Humans; China; Immunotherapy; Antigens, Neoplasm; Dendritic Cells
PubMed: 37699203
DOI: 10.1089/cbr.2023.0041 -
Nature Reviews. Immunology Feb 2022
Topics: Dendritic Cells; Humans
PubMed: 35027741
DOI: 10.1038/s41577-022-00675-7 -
Frontiers in Immunology 2022Gastrointestinal (GI) cancers occur in the alimentary tract and accessory organs. They exert a global burden with high morbidity and mortality. Inside the tumor... (Review)
Review
Gastrointestinal (GI) cancers occur in the alimentary tract and accessory organs. They exert a global burden with high morbidity and mortality. Inside the tumor microenvironment, dendritic cells (DCs) are the most efficient antigen-presenting cells and are necessary for adaptive immune responses such as T and B-cell maturation. However, the subsets of DCs revealed before were mostly based on flow cytometry and bulk sequencing. With the development of single-cell RNA sequencing (scRNA-seq), the tumor and microenvironment heterogeneity of GI cancer has been illustrated. In this review, we summarize the classification and development trajectory of dendritic cells at the single-cell level in GI cancer. Additionally, we focused on the interaction of DCs with T cells and their effect on the response to immunotherapy. Specifically, we focused on the newly identified tumor-infiltrating dendritic cells and discuss their potential function in antitumor immunity.
Topics: Gastrointestinal Neoplasms; Ascomycota; Immunotherapy; Dendritic Cells; Tumor Microenvironment
PubMed: 36505406
DOI: 10.3389/fimmu.2022.1007823 -
Molecular Carcinogenesis Feb 2022Presentation of tumor antigens is a critical step in producing a robust antitumor immune response. Classically tumor antigens are thought to be presented to both CD8 and... (Review)
Review
Presentation of tumor antigens is a critical step in producing a robust antitumor immune response. Classically tumor antigens are thought to be presented to both CD8 and CD4 T cells by professional antigen-presenting cells (pAPCs) like dendritic cells using major histocompatibility complexes (MHC) I and II. But recent evidence suggests that in the tumor microenvironment (TME) cells other than pAPCs are capable of presenting tumor antigens on both MHC I and II. The evidence currently available on tumor antigen presentation by epithelial cells, vascular endothelial cells (VECs), fibroblasts, and cancer cells is reviewed herein. We refer to these cell types in the TME as "amateur" APCs (aAPCs). These aAPCs greatly outnumber pAPCs in the TME and could, potentially, play a significant role in priming an antitumor immune response. This new evidence supports a different perspective on antigen presentation and suggests new approaches that can be taken in designing immunotherapies to increase T cell priming.
Topics: Antigen Presentation; Antigen-Presenting Cells; Antigens, Neoplasm; Dendritic Cells; Endothelial Cells; Humans; Tumor Microenvironment
PubMed: 34570920
DOI: 10.1002/mc.23354 -
Blood May 2021In this issue of , Gallego et al reveal new complexity in the relationship between the chemokine receptor, CXCR4, and trafficking of dendritic cells (DCs) from the skin...
In this issue of , Gallego et al reveal new complexity in the relationship between the chemokine receptor, CXCR4, and trafficking of dendritic cells (DCs) from the skin to regional lymph nodes (LNs).
Topics: Langerhans Cells; Skin; Skin Aging
PubMed: 34014296
DOI: 10.1182/blood.2020010619 -
Hematology/oncology Clinics of North... Jun 2020Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN).... (Meta-Analysis)
Meta-Analysis Review
Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It has been shown to be safe and effective in treatment-naïve and previously treated adult patients, with high rates of successful bridging to hematopoietic stem cell transplantation. The pediatric experience is more limited but demonstrates safety. Given the risk of potentially fatal capillary leak syndrome with tagraxofusp, judicious patient selection is recommended. Combination therapy with hypomethylating agents and/or BCL-2 inhibitors are rational next lines of investigation, especially in patients ineligible to receive high-dose chemotherapy.
Topics: Age Factors; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dendritic Cells; Disease Management; Humans; Myeloproliferative Disorders; Recombinant Fusion Proteins; Treatment Outcome
PubMed: 32336420
DOI: 10.1016/j.hoc.2020.01.005 -
Frontiers in Immunology 2019Cell reprogramming concepts have been classically developed in the fields of developmental and stem cell biology and are currently being explored for regenerative... (Review)
Review
Cell reprogramming concepts have been classically developed in the fields of developmental and stem cell biology and are currently being explored for regenerative medicine, given its potential to generate desired cell types for replacement therapy. Cell fate can be experimentally reversed or modified by enforced expression of lineage specific transcription factors leading to pluripotency or attainment of another somatic cell type identity. The possibility to reprogram fibroblasts into induced dendritic cells (DC) competent for antigen presentation creates a paradigm shift for understanding and modulating the immune system with direct cell reprogramming. PU.1, IRF8, and BATF3 were identified as sufficient and necessary to impose DC fate in unrelated cell types, taking advantage of Clec9a, a C-type lectin receptor with restricted expression in conventional DC type 1. The identification of such minimal gene regulatory networks helps to elucidate the molecular mechanisms governing development and lineage heterogeneity along the hematopoietic hierarchy. Furthermore, the generation of patient-tailored reprogrammed immune cells provides new and exciting tools for the expanding field of cancer immunotherapy. Here, we summarize cell reprogramming concepts and experimental approaches, review current knowledge at the intersection of cell reprogramming with hematopoiesis, and propose how cell fate engineering can be merged to immunology, opening new opportunities to understand the immune system in health and disease.
Topics: Animals; Cellular Reprogramming; Dendritic Cells; Hematopoiesis; Humans; Immunity; Immunotherapy
PubMed: 31921109
DOI: 10.3389/fimmu.2019.02809 -
Frontiers in Immunology 2023With the deepening of our understanding of adaptive immunity at the cellular and molecular level, targeting antigens directly to immune cells has proven to be a... (Review)
Review
With the deepening of our understanding of adaptive immunity at the cellular and molecular level, targeting antigens directly to immune cells has proven to be a successful strategy to develop innovative and potent vaccines. Indeed, it offers the potential to increase vaccine potency and/or modulate immune response quality while reducing off-target effects. With mRNA-vaccines establishing themselves as a versatile technology for future applications, in the last years several approaches have been explored to target nanoparticles-enabled mRNA-delivery systems to immune cells, with a focus on dendritic cells. Dendritic cells (DCs) are the most potent antigen presenting cells and key mediators of B- and T-cell immunity, and therefore considered as an ideal target for cell-specific antigen delivery. Indeed, improved potency of DC-targeted vaccines has been proved and . This review discusses the potential specific targets for immune system-directed mRNA delivery, as well as the different targeting ligand classes and delivery systems used for this purpose.
Topics: Dendritic Cells; Vaccines; Adaptive Immunity; T-Lymphocytes; Antigens
PubMed: 38090568
DOI: 10.3389/fimmu.2023.1294929 -
Journal of Cancer Research and Clinical... Jul 2021
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Biomarkers; Dendritic Cells; Humans; Immunophenotyping
PubMed: 33651141
DOI: 10.1007/s00432-021-03572-z